119 related articles for article (PubMed ID: 19541477)
1. Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
Collin SM; Metcalfe C; Donovan JL; Athene Lane J; Davis M; Neal DE; Hamdy FC; Martin RM
Eur J Cancer; 2009 Dec; 45(18):3254-61. PubMed ID: 19541477
[TBL] [Abstract][Full Text] [Related]
2. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
Collin SM; Metcalfe C; Donovan J; Lane JA; Davis M; Neal D; Hamdy F; Martin RM
BJU Int; 2008 Nov; 102(10):1400-6. PubMed ID: 18540932
[TBL] [Abstract][Full Text] [Related]
3. Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer.
Moore AL; Dimitropoulou P; Lane A; Powell PH; Greenberg DC; Brown CH; Donovan JL; Hamdy FC; Martin RM; Neal DE
BJU Int; 2009 Dec; 104(11):1592-8. PubMed ID: 19549125
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
5. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
Brindle LA; Oliver SE; Dedman D; Donovan JL; Neal DE; Hamdy FC; Lane JA; Peters TJ
BJU Int; 2006 Oct; 98(4):777-82. PubMed ID: 16978272
[TBL] [Abstract][Full Text] [Related]
6. Early diagnosis of prostate cancer in the Western Cape.
Heyns CF; Naudé AM; Visser AJ; Marais DC; Stopforth HB; Nyarko JK; Stellmacher GA
S Afr Med J; 2001 Aug; 91(8):679-84. PubMed ID: 11584784
[TBL] [Abstract][Full Text] [Related]
7. The association between sexual function and prostate cancer risk in US veterans.
Zapata DF; Howard LE; Frank J; Simon RM; Hoyo C; Grant DJ; Freedland SJ; Vidal AC
Asian J Androl; 2017; 19(2):191-195. PubMed ID: 27586025
[TBL] [Abstract][Full Text] [Related]
8. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.
Rosario DJ; Lane JA; Metcalfe C; Donovan JL; Doble A; Goodwin L; Davis M; Catto JW; Avery K; Neal DE; Hamdy FC
BMJ; 2012 Jan; 344():d7894. PubMed ID: 22232535
[TBL] [Abstract][Full Text] [Related]
9. Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.
Tilling K; Garmo H; Metcalfe C; Holmberg L; Hamdy FC; Neal DE; Adolfsson J; Martin RM; Davis M; Fall K; Lane JA; Adami HO; Bill-Axelson A; Johansson JE; Donovan JL
Eur Urol; 2010 Mar; 57(3):446-52. PubMed ID: 19303695
[TBL] [Abstract][Full Text] [Related]
10. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
11. [PSA testing, biopsy and cancer and benign prostate hyperplasia in France].
Tuppin P; Samson S; Fagot-Campagna A; Lukacs B; Alla F; Allemand H; Paccaud F; Thalabard JC; Vicaut E; Vidaud M; Millat B
Prog Urol; 2014 Jul; 24(9):572-80. PubMed ID: 24975792
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
Catalona WJ; Smith DS; Ornstein DK
JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
[TBL] [Abstract][Full Text] [Related]
13. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values.
Keetch DW; Catalona WJ; Smith DS
J Urol; 1994 Jun; 151(6):1571-4. PubMed ID: 7514690
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
Thompson IM; Pauler DK; Goodman PJ; Tangen CM; Lucia MS; Parnes HL; Minasian LM; Ford LG; Lippman SM; Crawford ED; Crowley JJ; Coltman CA
N Engl J Med; 2004 May; 350(22):2239-46. PubMed ID: 15163773
[TBL] [Abstract][Full Text] [Related]
15. Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).
Murad AS; Down L; Davey Smith G; Donovan JL; Athene Lane J; Hamdy FC; Neal DE; Martin RM
Int J Cancer; 2011 Mar; 128(6):1442-8. PubMed ID: 20506261
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
[TBL] [Abstract][Full Text] [Related]
17. A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.
Nordström T; Aly M; Eklund M; Egevad L; Grönberg H
Eur Urol; 2014 Jun; 65(6):1184-90. PubMed ID: 23891454
[TBL] [Abstract][Full Text] [Related]
18. Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy.
Singh R; Cahill D; Popert R; O'Brien TS
BJU Int; 2003 Dec; 92(9):932-5. PubMed ID: 14632850
[TBL] [Abstract][Full Text] [Related]
19. Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study.
Palsdottir T; Nordström T; Aly M; Lindberg J; Clements M; Egevad L; Grönberg H; Eklund M
PLoS One; 2019; 14(6):e0218280. PubMed ID: 31194822
[TBL] [Abstract][Full Text] [Related]
20. Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies.
Catalona WJ; Beiser JA; Smith DS
J Urol; 1997 Dec; 158(6):2162-7. PubMed ID: 9366336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
